SkinXCare | Integral cell-biology platform for the development of the first effective treatment of radiodermatitis.

Summary
InnoHealth Group is a private company born with the mission of offering novel dermatological formulations, with a major focus on the rational development (scientific-based approach) of new and more effective therapeutic solutions to dermatological diseases. Our vision is to become a leading player of the therapeutic dermatology and skin care markets segments, something that will be enabled thanks to our patented cell biology platform for the development of novel products. Our platform is the only one in the market that integrates novel bioinformatic tools based on cellular proteomic/kinome data (SkinSim and INCOS) and in vitro assays (SimDerma) for the rational design and development of new dermatological formulations. The combination of these tools in the platform allows identifying the molecular/celular targets involved in skin diseases and the combinations of active ingredients/compounds with the highest synergistic activity in these targets for disease treatment. This makes our platform a key enabling technology for the development of new dermatological products, especially in treatment of skin diseases without a known efficient therapeutic solution because of the complexity in the cellular and biochemical damages underlying such diseases. In the SkinXCare project we seek demonstrating the potential of our platform by its use in the development of the first effective treatment of radiodermatitis, a severe skin condition that affects cancer patients undergoing radiotherapy and still remains an unmet clinical condition. Thanks to the uniqueness of the solution proposed in the SkinXCare project, we seek becoming a leading player of therapeutic dermatology market. This market segment was valued at €24.5 billion on 2015 and is predicted to grow at a CAGR of 6.7% until 2025, key figures that further sustain the SkinXCare business opportunity.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/743887
Start date: 01-12-2016
End date: 31-03-2017
Total budget - Public funding: 71 429,00 Euro - 50 000,00 Euro
Cordis data

Original description

InnoHealth Group is a private company born with the mission of offering novel dermatological formulations, with a major focus on the rational development (scientific-based approach) of new and more effective therapeutic solutions to dermatological diseases. Our vision is to become a leading player of the therapeutic dermatology and skin care markets segments, something that will be enabled thanks to our patented cell biology platform for the development of novel products. Our platform is the only one in the market that integrates novel bioinformatic tools based on cellular proteomic/kinome data (SkinSim and INCOS) and in vitro assays (SimDerma) for the rational design and development of new dermatological formulations. The combination of these tools in the platform allows identifying the molecular/celular targets involved in skin diseases and the combinations of active ingredients/compounds with the highest synergistic activity in these targets for disease treatment. This makes our platform a key enabling technology for the development of new dermatological products, especially in treatment of skin diseases without a known efficient therapeutic solution because of the complexity in the cellular and biochemical damages underlying such diseases. In the SkinXCare project we seek demonstrating the potential of our platform by its use in the development of the first effective treatment of radiodermatitis, a severe skin condition that affects cancer patients undergoing radiotherapy and still remains an unmet clinical condition. Thanks to the uniqueness of the solution proposed in the SkinXCare project, we seek becoming a leading player of therapeutic dermatology market. This market segment was valued at €24.5 billion on 2015 and is predicted to grow at a CAGR of 6.7% until 2025, key figures that further sustain the SkinXCare business opportunity.

Status

CLOSED

Call topic

SMEInst-05-2016-2017

Update Date

26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.3. INDUSTRIAL LEADERSHIP - Innovation In SMEs
H2020-EU.2.3.1. Mainstreaming SME support, especially through a dedicated instrument
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-1-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector